Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of ASLAN001 in HER2-Amplified or HER1/HER2 Co-Expressing Gastric and Esophageal Cancer
KCT0000348Phase 2Not yet recruiting
- Sponsor
- Syneos Health
- Start
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of varlitinib in gastric adenocarcinoma, esophagogastric junction cancer, esophageal cancer, sponsored by Syneos Health. Planned start Mar 2012; status: not yet recruiting.
02
Drugs
varlitinib
03
Conditions
gastric adenocarcinomaesophagogastric junction canceresophageal cancer
Beyond the preview
Go deeper on KCT0000348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000348.